Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promega ADCC Reporter Bioassay Named to The Scientist Top 10 Innovations for 2013

Published: Wednesday, December 04, 2013
Last Updated: Wednesday, December 04, 2013
Bookmark and Share
Frozen, thaw-and-use cells greatly reduce assay variability.

Promega Corporation is pleased to announce that The Scientist has named the ADCC Reporter Bioassay to its 2013 Top 10 Innovations. The ADCC Reporter Bioassay is a surrogate assay for evaluating antibody-dependent, cell-mediated cytotoxicity (ADCC) of therapeutic mAbs, and it exhibits greatly reduced variability and is easier to perform than classic ADCC assays. ADCC is the primary mechanism of action of many mAb therapeutic drugs.

This innovation is transforming biologics drug development by allowing the biotech industry to more easily and reproducibly characterize mAb therapeutic drugs during manufacturing and lot release, as well as in earlier drug development stages such as clonal selection of antibodies.

The new ADCC Reporter Bioassay is available in kits with cells provided in frozen, thaw-and-use format, plus components to perform a homogeneous bioassay in a single day. The product replaces variable natural killer effector cells, typically primary in origin, with engineered effector cells that use a reporter gene readout approach. The effector cells, and control target cells, are ready to use without need for cell culture propagation.

The assay possesses all of the hallmarks of an optimal bioassay - excellent linearity, specificity, repeatability, precision and accuracy - and therefore can be used for potency lot release, stability indicating and antibody screening applications. Furthermore, the bioassay is sensitive enough to assess the impact of post-translational modifications, such as glycosylation and fucosylation, an area of intense exploration, on the potency of mAbs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!